We got an inside look at how the biotech Spark used mazes to develop a first-of-its-kind treatment for eye disease on the way to selling itself for $4.8 billion

We found this article at:

www.businessinsider.nl/gene-therapy-for-eye-disease-sparks-luxturna-clinical-trial-design-2019-8/